Enzymlogic Company Profile

Background

Enzymlogic, founded in 2013 and headquartered in Tres Cantos, Madrid, Spain, is a Contract Research Organization (CRO) specializing in kinetic profiling to accelerate drug discovery. The company's mission is to expedite the identification of promising compounds during the early phases of drug development, thereby enhancing the efficiency of the pharmaceutical industry. Enzymlogic's vision is to revolutionize drug discovery by providing precise kinetic data that informs medicinal chemistry and optimizes therapeutic outcomes. Operating within the biotechnology research sector, Enzymlogic holds a significant position in the industry by offering specialized services that bridge the gap between pharmacokinetics and pharmacodynamics.

Key Strategic Focus

Enzymlogic concentrates on the Hit to Lead (H2L) and Lead Optimization (LO) stages of drug discovery. The company's core objectives include:

• Optimized Kinetic Profiling: Utilizing advanced assays to deliver accurate, robust, and reproducible kinetic data, facilitating the identification of compounds with therapeutic potential.

• Therapeutic Targeting: Focusing on both reversible and irreversible inhibitors to assess their efficacy and safety profiles.

• Comprehensive Assay Development: Creating customized assays tailored to specific client requirements, ensuring precise and timely reporting of results.

Enzymlogic employs proprietary technologies such as KINETICfinder® and COVALfinder® platforms to provide detailed kinetic insights for reversible and irreversible inhibitors. These technologies are instrumental in understanding compound-target interactions, optimizing lead compounds, and building better models to define therapeutic windows.

Financials and Funding

Enzymlogic has secured funding from various public and private investors, recognizing the innovative nature of its technology and the expertise of its team. Notable funding milestones include:

• February 2014: Seed funding from Enisa.

• June 2019: Grant from the European Union.

• November 2019: Grant from the EIC Fund.

• May 2022: €2.2 million grant from the European Commission and the Spanish Innovation Agency (CDTI) to expand the KINETICfinder® platform and enhance its capabilities.

The capital raised is intended to support the development and scaling of Enzymlogic's technological platforms, expand its service offerings, and facilitate entry into new markets.

Pipeline Development

Enzymlogic's pipeline development is centered around the continuous enhancement of its kinetic profiling platforms:

• KINETICfinder®: A patented kinetic screening platform that delivers rapid and accurate compound-target interaction data, including Kd, kon, koff, and residence time. This platform aids in medicinal chemistry iteration and understanding PK/PD disconnects.

• COVALfinder®: A platform designed to provide in-depth understanding of the binding mechanism of reversible, reversible covalent, and irreversible drugs, offering kinetic data to predict structure-activity relationships and target engagement.

These platforms are continually refined to meet the evolving needs of the pharmaceutical and biotech industries, ensuring that Enzymlogic remains at the forefront of drug discovery innovation.

Technological Platform and Innovation

Enzymlogic's technological platforms are distinguished by their precision and adaptability:

• KINETICfinder®: Delivers rapid, reliable, and reproducible kinetic data, facilitating the selection of promising compounds for progression.

• COVALfinder®: Provides detailed insights into the binding mechanisms of various drug types, enhancing the prediction of therapeutic efficacy and safety.

These platforms employ advanced scientific methodologies, including high-throughput screening and kinetic assays, to provide comprehensive data that informs drug development decisions. The integration of these technologies enables Enzymlogic to offer a unique value proposition in the drug discovery process.

Leadership Team

Enzymlogic's leadership team comprises professionals with diverse expertise in biotechnology and drug discovery:

• Ana Corrionero Pérez: Focuses on supporting and developing the company to better serve clients.

• Patricia: Provides scientific and technical support to fully define projects with the highest integrity.

• Jeremy Hague: Seeks to understand how to add value to discovery efforts and brings together relevant experts.

• Niall Prendiville: Develops tools and models that underpin high-performing assays.

• José: Transforms research needs into assays that are accurate, robust, and reproducible.

• Tatiana: Specializes in data analysis, ensuring clients receive reliable information promptly.

• María: Generates dependable kinetic data for clients, central to the company's operations.

Market Insights and Dynamics

The market for drug discovery services, particularly in kinetic profiling, is characterized by rapid technological advancements and increasing demand for precision in early-stage drug development. Companies are seeking innovative solutions to streamline the discovery process and improve the success rates of clinical trials.

Competitor Analysis

Enzymlogic operates in a competitive landscape with several key players:

• BioAgilytix: Provides large-molecule bioanalysis for biologics and biosimilars development.

• Advion: Offers microfluidics and mass spectrometry products for clinical research.

• Tentamus: Delivers analytical and quality assurance services across diverse industries.

• Nordic Bioscience: Specializes in preclinical and clinical drug development.